Sunshine Homes Vill. Raipur, Opp. Gate No. 2 Amity University Sector – 126, Noida 201304

site-logo

— Recent Updates —

May 23, 2022

Cannabinoid hyperemesis syndrome: Causes, symptoms, and treatment

He also warned that people with serious mental illnesses, such as schizophrenia, should be cautious about marijuana use, as studies show cannabis can exacerbate the effects of those illnesses. Camilleri also said that cannabis use is positively correlated with anxiety and depression, and noted that doctors should treat the whole patient and not just the disorder. Ultimately, the only way to guarantee health is by totally abstaining, he added. If the patient quits cannabis consumption, vomiting due to CHS largely subsides. It’s possible that with lower amounts or lower frequency, patients might be able to use cannabis again, but the science is unclear. “There is evidence that if you send a message to the brain that competes with the message that’s causing the nausea, vomiting, that you can suppress it,” Camilleri said.

cannabinoid hyperemesis syndrome

Hyperemesis induced by cannabis

  • The authors stated, “—the toxic effects of neem oil are unlikely to be caused by its azadirachtin content.” p. 35.
  • Since the 1990s, there has been a progressive change in the composition of the plant, with increases in the tetrahydrocannabinol (THC) and a reduction of cannabidiol (CBD).6 This trend correlates with increased cannabis use.
  • The prevalence of cannabis CHS is expected to rise as legal restrictions on its recreational use decrease in several states.
  • Studies focused on individuals diagnosed with CHS, as well as those with comparable conditions like CVS, were selected.

In addition, frequent vomiting from any cause can lead to erosion of tooth enamel and potentially tooth loss, she adds. The biggest risk factor for CHS is heavy cannabis use, as in almost daily or multiple times per day over several years. People can develop the syndrome at any time, even after decades of prolonged use of cannabis. Two distinct cannabinoid receptors, CB1 and CB2, have been identified in human and animal models. The CB1 and CB2 receptors function as G-protein coupled receptors that act by inhibiting adenylate cyclase 7. In the brain, CB1 receptors are localized to the cerebral cortex, hypothalamus, anterior cingulate gyrus, hippocampus, cerebellum, and basal ganglia 8.

Patient consent for publication

cannabinoid hyperemesis syndrome

The metabolism of anandamide is principally carried out via fatty acid amide hydrolase (FAAH), whereas the major enzyme metabolizing 2-AG is monoacylglycerol lipase (MAGL) 18. Understanding the ECS and its effects on the vomiting center of the brain are fundamental to explain the effect of cannabis for this biphasic response 21. The ECS is composed of ligands, receptors, signaling, and enzymes (its regulators and inhibitors) 22.

What Causes CHS?

cannabinoid hyperemesis syndrome

It is not known why the syndrome develops in some, but not all, long-term marijuana users and why symptoms take longer to manifest in some patients than others. Although there were very few case studies involving CHS patients with eating disorders, bulimia might present in such a way that it could be confused with CHS. About 35% of individuals with some form of substance use disorder have an eating disorder (which typically precedes the substance use disorder) versus 5% of the general population 174. Since vomiting is a symptom of many conditions, CHS patients often undergo computed tomography scans, magnetic resonance imaging, gastric emptying tests, endoscopy, colonoscopy, even exploratory procedures before a CHS diagnosis is made 91.

cannabinoid hyperemesis syndrome

You could go about your day with an uneasy stomach, often worrying that you might vomit. You might experience abdominal pain, but it might be more of a dull ache than a sharp sensation. If you or someone you know has reached a point of “scromiting,” it’s definitely time to consult a Sobriety healthcare provider.

cannabinoid hyperemesis syndrome

  • These supportive treatments can help people during the hyperemesis stage of the condition, but recovery depends on the person stopping their use of marijuana.
  • Further initiatives are needed to determine this disease prevalence and its other epidemiological characteristics, natural history, and pathophysiology.
  • In addition, the use of a PPI reduces the risk of esophageal and gastric mucosal lesions, following excessive vomiting 19.
  • Clinical pharmacists can play an important role in the management of CHS patients through therapy recommendation.

“The brain’s endocannabinoid system modulates the stress response, and cannabis makes that pendulum swing further one way than the other,” which can trigger symptoms. In a 2019 review of 271 cases, researchers found that the mean age for having CHS was 30 and that 69 percent of people were male. They also found that daily use occurred in 68 percent of people with the syndrome, and the mean duration of cannabis use before the onset of CHS was 6.6 years. That said, “most people who smoke cannabis daily don’t get this,” says Christopher N. Andrews, a clinical professor of gastroenterology at the University of Calgary.

Cannabinoid Hyperemesis Syndrome Prevention

  • Further to this, abdominal discomfort can also occur and is thought to be due to THC-induced splanchnic vasodilation (and cutaneous vasoconstriction), a phenomenon known as “cutaneous-stealing syndrome” 8.
  • Further studies are also necessary to determine the causes of CHS and its risk factors.
  • The CB1 and CB2 receptors function as G-protein coupled receptors that act by inhibiting adenylate cyclase 7.

While patients benefit from rehydration and other forms of supportive care, the only effective treatment for CHS is marijuana cessation. Conventional antiemetics are not contraindicated but are generally ineffective likely because of the atypical mechanisms behind CHS. Gastric motility and gastroparesis must be discussed in the context of CHS. The enteric nervous system contains CB1 receptors, which, when activated, can inhibit GI motility by inhibiting the release of those transmitters that cause stomach contractions 47. This effect causes delayed gastric emptying and continues to inhibit transit through the small intestine. The effects are similar to gastroparesis and, thus, CHS may be caused by a functional gastroparesis.

cannabinoid hyperemesis syndrome

To make a diagnosis, your healthcare provider will conduct a thorough physical examination and ask you about your past health and current symptoms. It’s helpful to volunteer your history of cannabis use with your provider if you are not asked about it. Since there are so many active chemicals in cannabis, the exact cause of cannabinoid hyperemesis syndrome is unknown.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Posts

You are just a call away, call us now +91-8130238788, +91-9599373207